← Evidence map

ArticleMedComm2026

Efficacy and Safety of DNV3 (a Lymphocyte-activation Gene 3-blocking Antibody) Combined With Toripalimab and Chemotherapy in Advanced Melanoma: An Open-label, Single-arm Clinical Trial.

Jing Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2026

this paperpooled itcites it

Efficacy and Safety of DNV3 (a Lymphocyte-activation Gene 3-blocking Antibody) Combined With Toripalimab and Chemotherapy in Advanced Melanoma: An Open-label, Single-arm Clinical Trial. | OpenQuestion